Proteomics International Laboratories Ltd. · ASX:PIQ
Proteomics International Laboratories — Australasian Diabetes Congress 2021
7 slides from Proteomics International Laboratories's conference presentation, Aug 11, 2021
Slide 1: Diabetes treatment lowers PromarkerD risk score: Results presented at Australasian Diabetes Congress
ASX Release 11 August 2021 ASX code: PIQ For personal use only Diabetes treatment lowers PromarkerD risk score: Results presented at Australasian Diabetes Congress Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) is pleased to provide a copy of its conference presentati
Slide 2: About PromarkerD, references and contact
clinical variables (age, HDL-cholesterol and estimated glomerular filtration rate (eGFR)) [7]. In clinical studies published in leading journals PromarkerD correctly predicted up to 86% of otherwise healthy diabetics who went on to develop diabetic kidney disease within four years [8, 9]. The Promar
Slide 3: Canagliflozin attenuates PromarkerD diabetic kidney disease risk prediction scores
For personal use only Canagliflozin attenuates PromarkerD diabetic kidney disease risk prediction scores Kirsten E. Peters1,2, Katrina Spilsbury1, Jialin Xu3, Scott D. Bringans1, Timothy M.E. Davis2, Norman Rosenthal3, Michael K. Hansen3, Richard J. Lipscombe1 1 Proteomics International, Perth, West
Slide 4: Background & Aim
Background & Aim For personal use only ➢ Diabetic kidney disease (DKD) is the leading cause of end- stage renal disease.1 ➢ PromarkerD is a simple biomarker-based blood test that can predict future renal function decline in individuals with T2D and no existing DKD (eGFR ≥60 mL/min/1.73m2).2,3 ➢ Cana
Slide 5: Methods
Methods For personal use only ➢ PromarkerD scores were measured at baseline (Yr0) and Yr3 in 2,008 T2D participants without DKD# (n=629 placebo/n=1,379 CANA, mean age 62 years, 69% males, median diabetes duration 12 years).1 ➢ PromarkerD scores combine 3 protein biomarker concentrations (CD5L, ApoA4
Slide 6: ΔPromarkerD Scores by PromarkerD Risk Category
∆PromarkerD Scores by PromarkerD Risk Category For personal use only ➢ Across all participants, those on canagliflozin had decreased mean PromarkerD scores (Δ score: -1.0% (-1.9%, -0.1%); p=0.038), while those on placebo increased over the three-year period (Δ score: 3.9% (2.5%, 5.3%); p<0.001). The
Slide 7: Conclusions
Conclusions For personal use only ➢ This post-hoc analysis of data from 2,008 CANVAS participants with T2D and no DKD showed: ➢ Canagliflozin significantly lowered mean PromarkerD scores compared to placebo over 3 years. ➢ The greatest effect of canagliflozin was in those classified by PromarkerD as
Proteomics International Laboratories — Australasian Diabetes Congress 2021 on 6ix